• Something wrong with this record ?

Impact of dabigatran on platelet function and fibrinolysis

AE. Tsantes, E. Kyriakou, S. Bonovas, M. Chondrogianni, C. Zompola, C. Liantinioti, A. Simitsi, AH. Katsanos, M. Atta, I. Ikonomidis, V. Kapsimali, P. Kopterides, G. Tsivgoulis,

. 2015 ; 357 (1-2) : 204-8. [pub] 20150723

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020470

BACKGROUND: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF). METHODS: Consecutive patients with cerebrovascular diseases and NVAF that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous thrombin potential (ETP) and hemoclot thrombin inhibitors (HTI), were also performed in order to detect any possible correlation between dabigatran plasma levels, its anticoagulant activity and the intensity of platelet dysfunction or fibrinolysis. RESULTS: A total of nineteen patients fulfilled our inclusion criteria (mean age 62.3±7.2years; 47% males; median CHADS2-score: 3; interquartile range: 2-4). DE treatment was associated with a significant reduction of the lysis index (LI60) at 60min (p=0.036), and prolongation of the PFA-100 CEPI closure time (p=0.024). After dabigatran treatment, abnormal PFA-100 results were obtained in two patients (11%, 95% CI: 2%-33%). DE levels (determined by HTI) were strongly inversely correlated (rho=-0.85; p<0.001) with the area under the curve (AUC) values in ETP assay. Νo association was found between HTI and PFA-100 CEPI CT (p=0.64), or LI60 measurements (p=0.60). CONCLUSIONS: Our findings indicate that DE might affect platelet function and fibrinolysis and highlight the potential role of ETP as an alternative option in DE monitoring. The intensity and clinical relevance of DE antiplatelet and fibrinolytic effects require further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020470
003      
CZ-PrNML
005      
20160801111425.0
007      
ta
008      
160722s2015 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jns.2015.07.031 $2 doi
024    7_
$a 10.1016/j.jns.2015.07.031 $2 doi
035    __
$a (PubMed)26219486
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Tsantes, Argirios E $u Laboratory of Haematology & Blood Bank Unit, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
245    10
$a Impact of dabigatran on platelet function and fibrinolysis / $c AE. Tsantes, E. Kyriakou, S. Bonovas, M. Chondrogianni, C. Zompola, C. Liantinioti, A. Simitsi, AH. Katsanos, M. Atta, I. Ikonomidis, V. Kapsimali, P. Kopterides, G. Tsivgoulis,
520    9_
$a BACKGROUND: We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF). METHODS: Consecutive patients with cerebrovascular diseases and NVAF that were treated with DE in a tertiary university hospital. Fibrinolysis and platelet function were assessed by thromboelastometry (ROTEM) and platelet function analyzer (PFA)-100, respectively, before and after treatment with DE. Conventional coagulation tests, endogenous thrombin potential (ETP) and hemoclot thrombin inhibitors (HTI), were also performed in order to detect any possible correlation between dabigatran plasma levels, its anticoagulant activity and the intensity of platelet dysfunction or fibrinolysis. RESULTS: A total of nineteen patients fulfilled our inclusion criteria (mean age 62.3±7.2years; 47% males; median CHADS2-score: 3; interquartile range: 2-4). DE treatment was associated with a significant reduction of the lysis index (LI60) at 60min (p=0.036), and prolongation of the PFA-100 CEPI closure time (p=0.024). After dabigatran treatment, abnormal PFA-100 results were obtained in two patients (11%, 95% CI: 2%-33%). DE levels (determined by HTI) were strongly inversely correlated (rho=-0.85; p<0.001) with the area under the curve (AUC) values in ETP assay. Νo association was found between HTI and PFA-100 CEPI CT (p=0.64), or LI60 measurements (p=0.60). CONCLUSIONS: Our findings indicate that DE might affect platelet function and fibrinolysis and highlight the potential role of ETP as an alternative option in DE monitoring. The intensity and clinical relevance of DE antiplatelet and fibrinolytic effects require further investigation.
650    _2
$a senioři $7 D000368
650    _2
$a antitrombiny $x krev $x farmakologie $x terapeutické užití $7 D000991
650    _2
$a fibrilace síní $x krev $x farmakoterapie $7 D001281
650    _2
$a hemokoagulace $x účinky léků $x fyziologie $7 D001777
650    _2
$a trombocyty $x účinky léků $x metabolismus $7 D001792
650    _2
$a dabigatran $x krev $x farmakologie $x terapeutické užití $7 D000069604
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrinolýza $x účinky léků $x fyziologie $7 D005342
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pilotní projekty $7 D010865
650    _2
$a tromboelastografie $x metody $7 D013916
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kyriakou, Elias $u Laboratory of Haematology & Blood Bank Unit, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Bonovas, Stefanos $u Department of Pharmacology, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Chondrogianni, Maria $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Zompola, Christina $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Liantinioti, Chrissoula $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Simitsi, Athina $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Katsanos, Aristeidis H $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Atta, Maria $u Laboratory of Haematology & Blood Bank Unit, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece. $7 gn_A_00009839
700    1_
$a Ikonomidis, Ignatios $u Second Cardiology Department, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Kapsimali, Violetta $u Department of Microbiology, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Kopterides, Petros $u Second Department of Critical Care Medicine, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece.
700    1_
$a Tsivgoulis, Georgios $u Second Department of Neurology, "Attikon" University Hospital, School of Medicine, University of Athens, Athens, Greece; International Clinical Research Center, St. Anne's University Hospital in Brno, Brno, Czech Republic. Electronic address: tsivgoulisgiorg@yahoo.gr.
773    0_
$w MED00003004 $t Journal of the neurological sciences $x 1878-5883 $g Roč. 357, č. 1-2 (2015), s. 204-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26219486 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160801111652 $b ABA008
999    __
$a ok $b bmc $g 1155140 $s 944998
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 357 $c 1-2 $d 204-8 $e 20150723 $i 1878-5883 $m Journal of the neurological sciences $n J Neurol Sci $x MED00003004
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options